Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 95
Acronyms AACI Association of American Cancer Institutes ACOSOG American College of Surgeons Oncology Group ACRIN American College of Radiology Imaging Network ALL acute lymphoblastic leukemia AMA American Medical Association AML acute myeloid leukemia ASCO American Society of Clinical Oncology ASO administrative services only BIQSFP Biomarker, Imaging, and Quality of Life Studies Funding Program BUN blood urea nitrogen concentration caBIG Cancer Biomedical Informatics Grid CALGB Cancer and Leukemia Group B CAM complementary and alternative medicine CBER Center for Biologics Evaluation and Research CCOP Community Clinical Oncology Program CCSG Cancer Center Support Grant CDER Center for Drug Evaluation and Research CDRH Center for Devices and Radiological Health CEBP CCAAT/Enhancer Binding Protein 95

OCR for page 95
96 IMPLEMENTING A NATIONAL CANCER CLINICAL TRIALS SYSTEM CED coverage with evidence development CIRB Central Institutional Review Board CLIA Clinical Laboratory Improvement Amendments CME continuing medical education CMS Centers for Medicare and Medicaid Services COG Children’s Oncology Group CPC Cancer Prevention and Control CPT Common Procedural Terminology CRADA Cooperative Research and Development Agreement CRF case report form CT computed tomography CTAC Clinical and Translational Research Advisory Committee CTEP Cancer Therapy Evaluation Program CTSU Cancer Trials Support Unit CTWG Clinical Trials Working Group DCTD Division of Cancer Treatment and Diagnosis ECOG Eastern Cooperative Oncology Group EMA European Medicines Agency ERISA Employee Retirement Income Security Act FDA Food and Drug Administration FLT3/ITD fms-like tyrosine kinase receptor-3/internal tandem duplication FOA Funding Opportunity Announcement GOG Gynecological Oncology Group HCPCS Healthcare Common Procedure Coding System HER2 human epidermal growth factor receptor 2 HHS U.S. Department of Health and Human Services IDE investigational device exemption IND investigational new drug IOM Institute of Medicine IP intellectual property IRB Institutional Review Board IT information technology

OCR for page 95
97 ACRONYMS KRAS Kirsten ras oncogene MTA Material Transfer Agreement NCCN National Cooperative Cancer Network NCCTG North Central Cancer Treatment Group NCI National Cancer Institute NDA new drug applications NHBLI National Heart, Lung, and Blood Institute NIH National Institutes of Health NLM National Library of Medicine NSABP National Surgical Adjuvant Breast and Bowel Project OEWG Operational Efficiency Working Group OHRP Office for Human Research Protections OPEN Oncology Patient Enrollment Network OSU Ohio State University PET-CT positron emission tomography-computed tomography PhRMA Pharmaceutical Research and Manufacturers of America PI principal investigator RECIST Response Evaluation Criteria in Solid Tumors RFA Request for Applications RTOG Radiation Therapy Oncology Group RUC Relative Value Scale Update Committee SACHRP Secretary’s Advisory Committee on Human Research Protections SJO St. Joseph Hospital, Orange, California sNDA supplemental new drug application SPA Special Protocol Assessment SPORE Specialized Program of Research Excellence START Standard Terms of Agreement for Research Trials SWOG Southwest Oncology Group TAILORx Trial Assigning IndividuaLized Options for Treatment TARGET Therapeutically Applicable Research to Generate Effective Treatments

OCR for page 95